ArticleCardiology research2026
Predictive Value of the Pulmonary Artery Pulsatility Index in Pulmonary Arterial Hypertension: REVEAL Analysis.
Article in Cardiology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is growing interest in developing risk assessment tools/metrics to improve treatment, management, and outcomes for pulmonary arterial hypertension (PAH). This study investigated the association of the pulmonary artery pulsatility index (PAPi) with patient characteristics, hospitalization, and mortality. Methods: Data collected from the US-based Registry to Evaluate Early and Long-Term PAH Disease Management were stratified/analyzed according to baseline PAPi quartiles (36-month follow-up). Results: In total, 2,711 patients were included. Baseline demographic/clinical characteristics were similar; however, the lowest quartiles (< 3.55; ≥ 3.55 to < 5.5) had higher New York Heart Association/World Health Organization functional class, while those in the highest quartiles (≥ 5.5 to < 9.0; ≥ 9.0) had longer 6-min walk distance. Of 2,414 patients assessed for hospitalization, 1,326 (54.9%) were hospitalized. Lower PAPi correlated with increasing hospitalization probability (≥ 9.0 quartile, n = 291 (48.0%); ≥ 5.5 to < 9.0 quartile, n = 333 (54.8%); ≥ 3.55 to < 5.5 quartile, n = 340 (57.2%); and < 3.55 quartile, n = 362 (59.7%)). Of 681 (28.1%) patients who died, 150 (24.1%) were in the ≥ 9.0 quartile, 154 (25.5%) the ≥ 5.5 to < 9.0 quartile, 157 (26.7%) the ≥ 3.55 to < 5.5 quartile, and 220 (35.9%) the < 3.55 quartile (P < 0.001). Compared with the < 3.55 quartile, there was a 35.6%, 25.8%, and 23.3% reduction in mortality in the ≥ 9.0, ≥ 5.5 to < 9.0, and ≥ 3.55 to < 5.5 quartiles, respectively. Conclusions: PAPi may be a useful prognostic tool and long-term predictor of clinical events in PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.